MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

International Journal of Oncology
Ching Ching LeowYong Chang

Abstract

Angiopoietin 2 (Ang2) is an important regulator of angiogenesis, blood vessel maturation and integrity of the vascular endothelium. The correlation between the dynamic expression of Ang2 in tumors with regions of high angiogenic activity and a poor prognosis in many tumor types makes Ang2 an ideal drug target. We have generated MEDI3617, a human anti-Ang2 monoclonal antibody that neutralizes Ang2 by preventing its binding to the Tie2 receptor in vitro, and inhibits angiogenesis and tumor growth in vivo. Treatment of mice with MEDI3617 resulted in inhibition of angiogenesis in several mouse models including: FGF2-induced angiogenesis in a basement extract plug model, tumor and retinal angiogenesis. In xenograft tumor models, treatment with MEDI3617 resulted in a reduction in tumor angiogenesis and an increase in tumor hypoxia. The administration of MEDI3617 as a single agent to mice bearing human tumor xenografts resulted in tumor growth inhibition against a broad spectrum of tumor types. Combining MEDI3617 with chemotherapy or bevacizumab resulted in a delay in tumor growth and no body weight loss was observed in the combination groups. These results, combined with pharmacodynamic studies, demonstrate that treatment of tumor-be...Continue Reading

Citations

Nov 13, 2012·Acta Neuropathologica·Karl H PlateDaniel J Dumont
Feb 22, 2012·Journal of the National Cancer Institute·Tanja HolopainenKari Alitalo
Oct 15, 2014·Cancer Letters·Nikolett M Biel, Dietmar W Siemann
Jun 13, 2015·Atherosclerosis·Thomas L TheelenSeppo Ylä-Herttuala
Apr 5, 2016·Proceedings of the National Academy of Sciences of the United States of America·Teresa E PetersonRakesh K Jain
Jan 30, 2015·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Moritz Felcht, Markus Thomas
Aug 5, 2014·Cell Reports·Nicolò RigamontiMichele De Palma
Jun 23, 2016·Journal for Immunotherapy of Cancer·Vishwajith SridharanJonathan D Schoenfeld
Feb 13, 2016·Journal of Clinical Pathology·George JourPhyu P Aung
Aug 18, 2017·International Journal of Molecular Sciences·Deok-Hoon KongSukmook Lee
Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer
Apr 22, 2016·Science Translational Medicine·Sangyeul HanGou Young Koh
Oct 8, 2018·Journal of Molecular Neuroscience : MN·Harshini Chakravarthy, Vasudharani Devanathan
Jul 31, 2019·Journal of Cardiovascular Development and Disease·Anouar Hafiane
Jul 1, 2017·Angiogenesis·Claire Viallard, Bruno Larrivée
Sep 25, 2020·Biotechnology and Bioengineering·Pan LiuJing Jin
Aug 10, 2017·Molecular Medicine Reports·Nunzia CaporarelloCarmelina Daniela Anfuso
Jun 3, 2021·Journal of Clinical Medicine·Gaetano GalloGiuseppe Sammarco
Jun 29, 2021·Frontiers in Cell and Developmental Biology·Ruipu SunPing-Pui Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.